An editorial discusses the pragmatic options for clinicians in light of the findings of this study, which include “(1) prescribing other medications for lower urinary tract symptoms that are not known to increase risk of depression, (2) giving clear warning to all patients about the possible risks, (3) warning those who have had prior depression about the risks, (4) monitoring carefully for depression during 5ARI use, or (5) doing nothing, insofar as the absolute differences in risk were small and the events rare.”